Publications
Publications
Show Results For
- All HBS Web
(1,030)
- Faculty Publications (260)
Drug
→
- October 1997 (Revised September 2003)
- Case
Eli Lilly and Company: Drug Development Strategy (A)
By: Stefan H. Thomke, Ashok Nimgade and Paul Pospisil
Describes how Eli Lilly and Co. tries to accelerate its new drug development process with the aid of "combinatorial chemistry"--a rapidly emerging and revolutionary approach to preclinical drug discovery. The product manager of a potential blockbuster migraine drug... View Details
- August 1997
- Article
Preventable Adverse Drug Events in Hospitalized Patients: A Comparative Study of Intensive Care and General Care Units
By: D. J. Cullen, J. Sweitzer, D. W. Bates, E. Burdick, A. Edmondson and L. L. Leape
- September 1996
- Case
Food and Drug Administration: Business as Unusual at CDER
By: Steven C. Wheelwright and James Leonard
- 1996
- Chapter
The Determinants of Research Productivity in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- Article
Scale and Scope in Drug Development: Unpacking the Advantages of Size in Pharmaceutical Research
By: Rebecca M. Henderson and Iain Cockburn
- spring 1996
- Article
Scale, Scope and Spillovers: The Determinants of Research Productifity in Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- January 1996
- Case
Biogen, Inc.: rBeta Interferon Manufacturing Process Development
Biogen, Inc., a Cambridge, MA-based biotechnology company, is wrapping up a project to develop a new manufacturing process for a new drug product that will reposition the company from a purely research-oriented company to a fully integrated pharmaceutical manufacturing... View Details
- fall 1994
- Article
Racing to Invest? The Dynamics of Competition in Ethical Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- Article
Measuring Competence? Exploring Firm Effects in Drug Discovery
By: Rebecca M. Henderson and Ian Cockburn
- November 1993 (Revised January 2006)
- Supplement
Beech-Nut Nutrition Corporation (B)
By: Lynn S. Paine
Officials of the U.S. Food and Drug Administration (FDA) must decide whether to refer the Beech-Nut apple juice case to the Justice Department for criminal prosecution, and if so, whether to recommend prosecution of individual executives or of the company only. View Details
- September 1993
- Case
Manufacturing at ALZA: The Right Prescription? (A)
ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner... View Details
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (B)
ALZA, a drug delivery company, must decide what and for whom to manufacture. In the past, it has licensed to pharmaceutical companies its patented system for the slow release of drugs into the human system. Therefore the company has little experience in choice of drug... View Details
- September 1993
- Supplement
Manufacturing at ALZA: The Right Prescription? (C)
ALZA, a drug delivery company, considers marketing its own and other companies' products. The primary issue is whether to build an internal sales force focused on a few niche markets, to finance a sales force through alliances, or to acquire a marketing company. View Details
- June 1993
- Case
Boston Fights Drugs
- April 1993 (Revised October 1995)
- Case
ALZA and Bio-Electro Systems (A): Technological and Financial Innovation
By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details
- March 1993
- Supplement
Burroughs Wellcome and AZT (B)
Describes Burroughs Wellcome's response to protests over the pricing of its AIDS drug AZT in September 1989. Also presents short-term reactions by government officials, AIDS activists, and investors to Burroughs Wellcome's strategy. View Details
- February 1993 (Revised August 1995)
- Case
Medicare Payment for Drugs and Medical Devices
- October 1992 (Revised September 1993)
- Case
Nopane Advertising Strategy
By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details